BioRui Biotech Completes Pre-A Financing and Submits Registration Dossier Following Successful Clinical Enrollment

VCBeat exclusively learned that Bairui ShengwuKeji (referred to as "Bairui Bio") completed its Pre-A round of financing at the beginning of the year. This round of financing was jointly invested by S&C Capital, Norden Ventures, and Ningbo Venture Capital Guidance Fund. The funds will mainly be used to advance the clinical trials, registration applications, and commercialization layout of the company's core product, high-strength absorbable sports medicine products.

Bairui ShengwuKeji, founded in 2021, focuses on building a high-strength absorbable product technology platform. The company’s first product line of absorbable sports medicine products is currently dominated by imported brands in the Chinese market. Due to issues such as material brittleness and insufficient strength after simple injection molding, absorbable materials often lead to clinical implant failures like breakage and difficulties in developing micro absorbable anchors for small joints. Bairui ShengwuKeji has significantly increased the strength of its absorbable sports medicine products using core technology, with some products achieving twice the strength of imported alternatives, effectively addressing existing clinical challenges in absorbable sports medicine.

Currently, all absorbable sports medicine products of Bairui ShengwuKeji have been successfully implanted in animal trials. Some animal experiments have been implanted for nearly one and a half years, with efficacy and safety comparable to imported products. Meanwhile, one absorbable sports medicine product has successfully completed clinical enrollment, and its performance has been highly praised by clinicians. It is expected to complete the certification of five Class III sports medicine products by 2025.

Founder of Bairui ShengwuKeji, Zhang JunpingSaid: "Based on the completed type inspection, animal experiments, and clinical trial results, the performance of Bairui ShengwuKeji's self-developed absorbable sports medicine products is superior to imported products, effectively addressing existing clinical issues and gaining recognition from clinicians. Next, Bairui will actively expand the market, hoping for the product to enter clinical use as soon as possible and achieve import substitution at an early date."

Wu Jialu, Founding Partner of PickCap CapitalSaid: "Bairui's proprietary material enhancement technology process, which has proven its unique value in clinical trials, effectively addresses the critical clinical issue of insufficient mechanical strength in absorbable implants, elevating the performance of domestically produced absorbable sports medicine products to a new level. We are honored to partner with Bairui and support its continued expansion in the absorbable medical device field."

Zhang Zhao, General Manager of Ningbo Nuodeng Venture CapitalSaid: "The sports medicine industry is currently in a period of rapid development. As an emerging force in domestically produced alternatives, Bairui ShengwuKeji has addressed clinical pain points by utilizing self-developed core technologies and material formulations to significantly enhance the strength of absorbable sports medicine products, with technical specifications comparable to similar foreign products. We are honored to witness the growth of Bairui ShengwuKeji as early investors. Gaining clinical approval is a crucial step for future market entry, and we firmly believe that under the leadership of Founder Zhang, the company's products will quickly integrate into the healthcare system, truly benefiting patients worldwide."

Ningbo Venture Capital Guidance FundBairui ShengwuKeji focuses on the field of sports medicine within the four major categories of orthopedics. It has independent intellectual property rights in products such as absorbable suture anchors and absorbable interface screws. The mechanical properties, such as maximum torque and bending strength, are comparable to imported products, effectively addressing the clinical issue of insufficient strength in absorbable materials. This investment in Bairui ShengwuKeji will help China reduce its reliance on imported sports medicine consumables, enhance the industry's independent innovation capabilities, and fully reflects the support of the municipal venture capital guidance fund for small and medium-sized technology enterprises. The municipal venture capital guidance fund will continue to shoulder the social responsibility of promoting local industrial transformation and upgrading, as well as serving the high-quality development of the real economy.